US Bancorp
TRDA icon

US Bancorp’s Entrada Therapeutics TRDA Stock Holding History

US Bancorp’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-70
Closed -$883 – 4342
2026
Q1 		$883 Buy
+70
New +$802 ﹤0.01% 3953
2025
Q3 		– Sell
-2,868
Closed -$19.3K – 4287
2025
Q2 		$19.3K Sell
2,868
-283
-9% -$2.28K ﹤0.01% 3180
2025
Q1 		$28.5K Buy
3,151
+493
+19% +$6.14K ﹤0.01% 3017
2024
Q4 		$46K Hold
2,658
– – ﹤0.01% 2780
2024
Q3 		$42.5K Buy
+2,658
New +$41.9K ﹤0.01% 2821

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

US Bancorp's TRDA Position: Q2 2026 in Review

US Bancorp sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 70 shares — an estimated $883 sold.

US Bancorp first reported a position in TRDA in Q3 2024 and held it in 5 quarters. The position peaked at $46K in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • US Bancorp reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • US Bancorp sold 70 Entrada Therapeutics shares in Q2 2026, an estimated $883.
  • US Bancorp first reported a position in Entrada Therapeutics in Q3 2024 and held it in 5 quarters.
  • US Bancorp's Entrada Therapeutics position peaked at $46K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.